Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Bristol-Myers Squibb describes potent and selective beta3-adrenoceptor agonist

Oct. 25, 1996

Lilly claims compounds for menopausal disorders

Oct. 25, 1996

Antiobesity proteins described by Lilly

Oct. 25, 1996

First and only Estrophasic oral contraceptive approved

Oct. 18, 1996

Menorest approved in Belgium

Oct. 18, 1996

Serono's recombinant human growth hormone approved

Oct. 18, 1996

JT and Tularik to develop new antidiabetic agents

Oct. 18, 1996

Novo Nordisk enters collaboration on PTPase inhibitors

Oct. 18, 1996

U.S. patent covers Celtrix's SomatoKine

Oct. 18, 1996

New NPY antagonists from Warner-Lambert

Oct. 18, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...